• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Martell Bridget A (Amendment)

    11/3/23 11:43:16 AM ET
    $ADXS
    Major Pharmaceuticals
    Health Care
    Get the next $ADXS alert in real time by email
    SEC FORM 3/A SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Martell Bridget A

    (Last) (First) (Middle)
    9 DEER PARK DRIVE, SUITE K-1

    (Street)
    MONMOUTH JUNCTION NJ 08852

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/18/2023
    3. Issuer Name and Ticker or Trading Symbol
    Ayala Pharmaceuticals, Inc. [ ADXS ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    11/01/2023
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Roy Golan, as attorney-in-fact for the Reporting Person 11/03/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ADXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)

      SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

      2/14/24 4:26:22 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Advaxis, Inc. (Amendment)

      SC 13D/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

      2/12/24 11:58:05 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)

      SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

      2/12/24 8:27:51 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care

    $ADXS
    Leadership Updates

    Live Leadership Updates

    See more
    • OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

      Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

      1/29/25 9:22:00 AM ET
      $ADXS
      $OSTX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director

      SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company's Board of Directors as an independent non-executive director, effective on March 31, 2021. Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America's best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biophar

      4/2/21 7:33:00 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care

    $ADXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Israel Biotech Fund I, L.P.

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      3/6/24 7:13:01 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Israel Biotech Fund I, L.P. exercised 27,847,159 shares at a strike of $0.40 and covered exercise/tax liability with 5,294,486 shares (SEC Form 4)

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      2/12/24 2:16:21 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Israel Biotech Fund I, L.P.

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      11/21/23 9:04:41 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care

    $ADXS
    SEC Filings

    See more

    $ADXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ADXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 15-12G filed by Advaxis, Inc.

      15-12G - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      5/9/24 4:05:37 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)

      10-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/26/24 5:03:01 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)

      8-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/19/24 7:50:34 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Israel Biotech Fund I, L.P. bought 1,317,716 shares (SEC Form 4)

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      10/31/23 7:08:02 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

      Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

      1/29/25 9:22:00 AM ET
      $ADXS
      $OSTX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

      MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the "SEC") to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to suspend its reporting obligations under Section 15(d) of the Exchange Act. The Company's obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Comp

      5/9/24 4:10:00 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

      MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (NASDAQ:IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an additional $37.5 million in development and commercial milestone payments. "We are pleased that AL102 will now be advanced by the highly experienced team at Immunome," said Ken Berlin, President and

      3/26/24 8:00:00 AM ET
      $ADXS
      $IMNM
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ADXS
    Financials

    Live finance-specific insights

    See more
    • Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

      Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss updated Phase 2 results on Wednesday, June 7 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced further results from the Phase 2 (Part A) segment of the RINGSIDE study evaluating AL102 in desmoid tumors. The results were presented in a Poster Discussion Session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 3. AL102 is a once-daily, po

      6/5/23 8:00:00 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

      REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the "Company," "New Ayala," "we," "us" or "our") (OTCQX:ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022. Management Commentary "We were pleased to close our previously announced merger in January 2023," said Kenneth A. Berlin, President and Chief Executive Officer of the Company. "Our immediate priorities include executing on Part B of the ongoing registration-enabling RINGSIDE study evaluating AL102 in desmoid tumors. We believe that AL102 has best in class potential and, if approved, m

      2/10/23 7:00:31 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

      Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi

      10/19/22 6:30:00 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary